Literature DB >> 35460424

ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma.

Benjamin Purow1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35460424      PMCID: PMC9435478          DOI: 10.1093/neuonc/noac103

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  7 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

2.  Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Authors:  Isabel Arrillaga-Romany; Yazmin Odia; Varun V Prabhu; Rohinton S Tarapore; Krystal Merdinger; Martin Stogniew; Wolfgang Oster; Joshua E Allen; Minesh Mehta; Tracy T Batchelor; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

3.  Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Authors:  Andrew S Chi; Rohinton S Tarapore; Matthew D Hall; Nicole Shonka; Sharon Gardner; Yoshie Umemura; Ashley Sumrall; Ziad Khatib; Sabine Mueller; Cassie Kline; Wafik Zaky; Soumen Khatua; Shiao-Pei Weathers; Yazmin Odia; Toba N Niazi; Doured Daghistani; Irene Cherrick; David Korones; Matthias A Karajannis; Xiao-Tang Kong; Jane Minturn; Angela Waanders; Isabel Arillaga-Romany; Tracy Batchelor; Patrick Y Wen; Krystal Merdinger; Lee Schalop; Martin Stogniew; Joshua E Allen; Wolfgang Oster; Minesh P Mehta
Journal:  J Neurooncol       Date:  2019-08-27       Impact factor: 4.130

4.  Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.

Authors:  Justyna M Przystal; Chiara Cianciolo Cosentino; Sridevi Yadavilli; Jie Zhang; Sandra Laternser; Erin R Bonner; Rachna Prasad; Adam A Dawood; Nina Lobeto; Wai Chin Chong; Matt C Biery; Carrie Myers; James M Olson; Eshini Panditharatna; Bettina Kritzer; Sulayman Mourabit; Nicholas A Vitanza; Mariella G Filbin; Geoffry N de Iuliis; Matthew D Dun; Carl Koschmann; Jason E Cain; Michael A Grotzer; Sebastian M Waszak; Sabine Mueller; Javad Nazarian
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

5.  Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.

Authors:  Paul R Graves; Lucas J Aponte-Collazo; Emily M J Fennell; Adam C Graves; Andrew E Hale; Nedyalka Dicheva; Laura E Herring; Thomas S K Gilbert; Michael P East; Ian M McDonald; Matthew R Lockett; Hani Ashamalla; Nathaniel J Moorman; Donald S Karanewsky; Edwin J Iwanowicz; Ekhson Holmuhamedov; Lee M Graves
Journal:  ACS Chem Biol       Date:  2019-05-01       Impact factor: 4.634

6.  GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.

Authors:  Robbie G Majzner; Sneha Ramakrishna; Kristen W Yeom; Shabnum Patel; Harshini Chinnasamy; Liora M Schultz; Rebecca M Richards; Li Jiang; Valentin Barsan; Rebecca Mancusi; Anna C Geraghty; Zinaida Good; Aaron Y Mochizuki; Shawn M Gillespie; Angus Martin Shaw Toland; Jasia Mahdi; Agnes Reschke; Esther H Nie; Isabelle J Chau; Maria Caterina Rotiroti; Christopher W Mount; Christina Baggott; Sharon Mavroukakis; Emily Egeler; Jennifer Moon; Courtney Erickson; Sean Green; Michael Kunicki; Michelle Fujimoto; Zach Ehlinger; Warren Reynolds; Sreevidya Kurra; Katherine E Warren; Snehit Prabhu; Hannes Vogel; Lindsey Rasmussen; Timothy T Cornell; Sonia Partap; Paul G Fisher; Cynthia J Campen; Mariella G Filbin; Gerald Grant; Bita Sahaf; Kara L Davis; Steven A Feldman; Crystal L Mackall; Michelle Monje
Journal:  Nature       Date:  2022-02-07       Impact factor: 49.962

7.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.